Log In
BCIQ
Print this Print this
 

bafetinib (Bafetinib) (formerly INNO-406, NS-187)

  Manage Alerts
Collapse Summary General Information
Company Nippon Shinyaku Co. Ltd.
DescriptionDual BCR-ABL tyrosine kinase and Lyn kinase (LYN) inhibitor
Molecular Target BCR-ABL tyrosine kinase (BCR-ABL) ; Lyn kinase (LYN)
Mechanism of ActionBCR-ABL tyrosine kinase inhibitor; Lyn kinase inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationChronic lymphocytic leukemia (CLL)
Indication DetailsTreat B cell chronic lymphocytic leukemia (CLL)
Regulatory Designation
PartnerCytRx Corp.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today